Hemophilia News Today

Hemophilia News Today is an online resource that offers daily news on research, scientific developments, and helpful tips for individuals with Hemophilia and their caregivers.

Consumer

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#514966

United States

#131255

Health/Health Conditions and Concerns

#313

Traffic sources

Monthly visitors

Articles

Hympavzi lowers bleeding rates for hemophilia patients: Trial data

2 days ago | hemophilianewstoday.com | Marisa Wexler

Preventive treatment with Hympavzi (marstacimab-hncq) can effectively reduce bleeding rates in people with hemophilia A or B who have inhibitors, or antibodies against standard replacement therapies, according to top-line data from a Phase 3 clinical trial. Hympavzi’s developer Pfizer said it’s now planning to discuss these data with regulatory authorities in hopes of getting the prophylactic (preventive) therapy approved for hemophilia patients who have inhibitors.
Direct switch from Hemlibra to investigational Mim8 well tolerated

5 days ago | hemophilianewstoday.com | Steve Bryson

Directly switching from Hemlibra (emicizumab) to Novo Nordisk‘s investigational Mim8 (denecimig) was well tolerated in adults and adolescents with hemophilia A, regardless of whether they had inhibitors or not. That’s according to results from the now-completed Phase 3b FRONTIER5 study (NCT05878938), which assessed the safety of switching between the two preventive therapies without a washout period or a Mim8 loading dose in 61 people 12 years and older with hemophilia .
Immune tolerance induction lowers treatment costs, if successful

2 weeks ago | hemophilianewstoday.com | Andrea Lobo

Successful immune tolerance induction (ITI) — a type of treatment that aims to re-educate the immune system to prevent the formation of inhibitors, or neutralizing antibodies targeting clotting factors — was associated with lower treatment costs in hemophilia A patients with inhibitors, a study in Brazil reported. Conversely, treatment costs were up to 7.5 times higher in patients for whom ITI failed.
CAR T-cell therapy successfully treats man's acquired hemophilia A

3 weeks ago | hemophilianewstoday.com | Marisa Wexler

CAR T-cell therapy, a type of treatment that weaponizes the body’s immune system and was originally developed to treat cancer, for the first time successfully treated a patient with acquired hemophilia A (AHA), a study reported. The study, “Anti-CD19 CAR-T cell therapy for acquired hemophilia A,” was published in Leukemia. Hemophilia A is marked by a deficiency in a clotting protein called factor VIII (FVIII).
Jivi wins FDA approval to treat hemophilia A in kids as young as 7

1 month ago | hemophilianewstoday.com | Marisa Wexler

Jivi (damoctocog alfa pegol) has received approval from the U.S. Food and Drug Administration (FDA) that now extends to children with hemophilia A as young as 7 years old. Jivi had previously been authorized for hemophilia A patients 12 and older.
More preventive treatment options needed, researchers say

1 month ago | hemophilianewstoday.com | Margarida Maia

Prophylactic (preventive) treatment for hemophilia A and B is generally more effective than on-demand treatment in reducing the frequency of bleeding, but the benefit is not as clear in patients who have developed inhibitors that limit how well replacement clotting factors work. That’s according to real-world data from explorer6 (NCT03741881), a non-interventional study sponsored by Novo Nordisk that ran across 33 countries.
Little testing done for girls at risk of hemophilia carrier status: Study

1 month ago | hemophilianewstoday.com | Patricia Inacio

A single-center U.S. study found relatively little genetic testing was done for girls with a 50% risk of being a hemophilia carrier — people with the altered gene who don’t have hemophilia themselves but can pass it to their children — over a four-year period in Washington state. Specifically, the testing — followed by genetic counseling — was conducted for about one-quarter of young girls offered such services at Seattle Children’s Hospital, according to the findings of the retrospective study.
People with bleeding disorders are living longer, but are we prepared?

1 month ago | hemophilianewstoday.com | Jennifer Lynne

I never used to think about aging because I was too focused on surviving the present: heavy periods, chronic anemia, and endless insurance hurdles. But lately, I’ve started to feel the shift. My joints take longer to recover. Mornings come with stiffness. Even the swelling from a minor finger bleed lingers for weeks. The truth is, I’m aging with hemophilia — and no one ever told me what that would look like.
Blood group O not tied to inhibitor risk in children with severe hem A

1 month ago | hemophilianewstoday.com | Patricia Inacio

Children with severe hemophilia A with blood group O are not at increased risk of developing neutralizing antibodies against factor VIII (FVIII) replacement therapy, a study found. The study, “Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group,” was published in Haemophilia.
Love is like a garden that needs tending to by both partners

1 month ago | hemophilianewstoday.com | Alliah Czarielle

I recently stumbled across a passage on social media referring to relationships: “If you want a garden? Take care of it. You want love? Love them.”Something about those simple words struck a chord with me. Instinctively, I forwarded it to my husband, Jared. “This is exactly why I’ve been wanting to work on myself,” he responded.